D. Boral Capital Initiates Coverage on Tevogen Bio (NASDAQ:TVGN)

Analysts at D. Boral Capital initiated coverage on shares of Tevogen Bio (NASDAQ:TVGN) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock.

Tevogen Bio Trading Down 7.8 %

TVGN opened at $1.18 on Tuesday. The firm has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.14. Tevogen Bio has a 1 year low of $0.26 and a 1 year high of $8.49.

Hedge Funds Weigh In On Tevogen Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC boosted its position in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. Northern Trust Corp lifted its position in shares of Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after buying an additional 13,595 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after acquiring an additional 16,695 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Tevogen Bio in the 4th quarter worth $38,000. Finally, XTX Topco Ltd purchased a new position in Tevogen Bio during the fourth quarter valued at $55,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.